PROPRANOLOL HYDROCHLORIDE- propranolol hydrochloride tablet

País: Estados Unidos

Idioma: inglés

Fuente: NLM (National Library of Medicine)

Ingredientes activos:

PROPRANOLOL HYDROCHLORIDE (UNII: F8A3652H1V) (PROPRANOLOL - UNII:9Y8NXQ24VQ)

Disponible desde:

Proficient Rx LP

Vía de administración:

ORAL

tipo de receta:

PRESCRIPTION DRUG

indicaciones terapéuticas:

Propranolol hydrochloride tablets USP are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Propranolol hydrochloride tablets USP are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Propranolol hydrochloride tablets USP are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Propranolol hydrochloride tablets USP are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Propranolol hydrochloride tablets USP are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indica

Resumen del producto:

Propranolol Hydrochloride Tablets USP 40 mg – Green, round, convex, debossed tablets on one side with PLIVA 469 and scored on the other side. Available in bottles of 30s. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). PROTECT FROM LIGHT. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured In Czech Republic By: TEVA CZECH INDUSTRIES s.r.o. Opava-Komarov, Czech Republic Manufactured For: TEVA PHARMACEUTICALS USA Sellersville, PA 18960 Rev. B 10/2011 Repackaged by: Proficient Rx LP Thousand Oaks, CA 91320

Estado de Autorización:

Abbreviated New Drug Application

Ficha técnica

PROPRANOLOL HYDROCHLORIDE- PROPRANOLOL HYDROCHLORIDE TABLET
PROFICIENT RX LP
----------
PROPRANOLOL HYDROCHLORIDE
TABLETS USP
467
468
469
470
471
DESCRIPTION
Propranolol hydrochloride USP is a synthetic beta-adrenergic receptor
blocking agent chemically
described as 2-Propanol,
1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride,(±)-.
Its
structural formula is:
C
H NO •HCl M.W. 295.80
Propranolol hydrochloride USP is a stable, white, crystalline solid
which is readily soluble in water
and in ethanol.
Propranolol hydrochloride tablets USP are available as tablets for
oral administration containing either
10 mg, 20 mg, 40 mg, 60 mg, or 80 mg of propranolol hydrochloride,
USP. Propranolol hydrochloride
tablets USP also contain lactose anhydrous, magnesium stearate,
microcrystalline cellulose, and sodium
starch glycolate. Color additives include FD&C Yellow no. 6 aluminum
lake (10 mg and 80 mg), D&C
Yellow no. 10 aluminum lake (10 mg, 40 mg, and 80 mg), FD&C Blue no. 1
aluminum lake (20 mg and
40 mg) and FD&C Red no. 40 aluminum lake (60 mg).
CLINICAL PHARMACOLOGY
GENERAL
Propranolol is a nonselective beta-adrenergic receptor blocking agent
possessing no other autonomic
nervous system activity. It specifically competes with beta-adrenergic
receptor agonist agents for
available receptor sites. When access to beta-receptor sites is
blocked by propranolol, the
chronotropic, inotropic, and vasodilator responses to beta-adrenergic
stimulation are decreased
proportionately. At dosages greater than required for beta-blockade,
propranolol also exerts a
quinidine-like or anesthetic-like membrane action, which affects the
cardiac action potential. The
significance of the membrane action in the treatment of arrhythmias is
uncertain.
MECHANISM OF ACTION
16
21
2
The mechanism of the antihypertensive effect of propranolol has not
been established. Factors that may
contribute to the antihypertensive action include: (1) decreased
cardiac output, (2) inhibition of renin
release by the kidneys, and (3) diminution of toni